Inventory Operations and Control Senior Specialist at Bristol-Myers Squibb

Leiden, South Holland, Netherlands

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, Life SciencesIndustries

Requirements

8+ years’ relevant experience with materials management, inventory management and/or supply chain (preferred but not required within cGMP operations)
Strong knowledge of inventory management within ERP environment
Lean/Six Sigma Yellow Belt or Green Belt experience preferred

Responsibilities

Author SOP revisions and change controls regarding inventory control
Oversee inventory document archival
Oversee inventory write-off process (Disposal Request) for expired materials. Partner with external service provider & Site Security to manage & witness physical destruction of materials
Collaborate with the Cell Therapy Materials Operations team to ensure all rejected and obsolete materials are removed from use in accordance with SOPs
Maintain and communicate performance metrics for Inventory Control function
Manage the physical cycle count program by verifying SAP inventory v. physical counts for on-site and offsite locations
Conduct inventory reconciliation and inventory audits; investigate discrepancies and adjust errors
Maintain a constant state of quality & financial compliance/audit readiness
Manage accurate inventory of direct GMP materials
Plan procurement of direct and indirect materials
Drive material release
Monitor and control days on hand (DOH) of all type of inventories

Skills

Inventory Management

Operations Control

Supply Chain

Manufacturing Operations

Cell Therapy

Production Optimization

GMP

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free